Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc.
Ryan Allway
February 2nd, 2021
Psychedelics
Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce a strategic partnership with neuroscience and technology leader, HealthTech Connex Inc.
Upon approval of the Company’s Licensed Dealer application, the Company’s subsidiary, Havn Labs, will be a preferred psychedelic supply partner for future clinical trials launched by HealthTech Connex’s Centre for Neurology Studies. In addition, HealthTech Connex will promote Havn Life’s library of naturally derived compounds to its other clinical trial partners and be a preferred partner for the execution of Havn Life clinical trials.
As an innovative company working to bridge the gap between research and real-world applications in advanced brain care, HealthTech Connex has been a pioneer in the field of brain research since its founding in 2013. The British Columbia-based organization uses technology, clinics, and clinical trials to translate neuroscience innovations into improved care for a variety of neurological conditions.
The partnership is a significant milestone for Havn Life, representing the company’s first clinical trial execution agreement. Establishing this link with HealthTech Connex also enables Havn Life’s own researchers to draw on the wealth of neuroscientific and technological expertise that HealthTech Connex brings. President and Chief Scientific Officer of HealthTech Connex, Dr. Ryan C. N. D’Arcy, is an established international leader in neurotechnology and neuroscience innovation. Dr. D’Arcy has led large health technology clusters, successfully brought brain technology products and services to market, and attracted more than $85 million in competitive research and innovation funding through prominent academic roles within Canada’s top universities and the National Research Council of Canada.
In 2019, Health Canada approved the NeuroCatch Platform, a class II medical device developed by HealthTech Connex that conducts a rapid 6-minute scan to measure and report on cognitive brain function. Researchers use this technology to gain insight into a range of common neurological conditions, including concussion and brain injury; dementia and neurological disease; post-traumatic stress disorder (PTSD) and mental health; and brain performance and human optimization. Given Havn Life’s deep commitment to the study of PTSD and human optimization, along with its focus on the Veteran community, the partnership brings significant benefit for both organizations. Havn Life will assist HealthTech Connex in expanding the use of NeuroCatch technology to psilocybin clinical trials.
“We’re thrilled to enter into this strategic partnership,” noted Tim Moore, CEO of Havn Life. “HealthTech Connex is a leader in the science and technology of brain health. NeuroCatch technology will be able to provide objective and sensitive cognitive brain evaluations that are otherwise not available to researchers. By supplying their clinical trials with our naturally derived psychedelic compounds, we’ll learn a tremendous amount about the applications of these compounds in several key areas of neuroscience and mental health.”
“Havn Life is at the forefront of extracting quality-controlled, naturally-derived psychedelic compounds. We’re fascinated by the therapeutic potential of these compounds across a wide range of cognitive and mental health applications, so it was essential for us to find a rigorous, science-driven supply partner like Havn Life,” said Sonia Brodie, VP Services at HealthTech Connex.
With a steady supply of Havn Life’s quality controlled compounds, The Centre for Neurology Studies at HealthTech Connex will be able rapidly and objectively evaluate changes in cognitive brain health in order to continue leading the way in the clinical science of brain health and human optimization.
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer
About Havn Life Sciences Inc.
Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter, Instagram, and Youtube.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
TruTrace Technologies has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry.
MichiCann Medical Inc. owns or controls 11 medical cannabis dispensaries in Michigan and is in the final stages to acquire another 11 shops, as well as three indoor cultivation facilities in the state.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
